Integra LifeSciences (NASDAQ:IART) Issues Q2 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.440-0.520 for the period, compared to the consensus EPS estimate of 0.530. The company issued revenue guidance of $410.0 million-$425.0 million, compared to the consensus revenue estimate of $425.3 million. Integra LifeSciences also updated its FY 2026 guidance to 2.400-2.500 EPS.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wells Fargo & Company upgraded shares of Integra LifeSciences to a “hold” rating in a report on Wednesday, March 18th. Citigroup cut their price target on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a report on Wednesday, March 11th. Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Argus restated a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $14.20.

Integra LifeSciences Price Performance

IART traded up $2.55 during midday trading on Tuesday, hitting $13.20. The company had a trading volume of 1,503,242 shares, compared to its average volume of 796,978. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $16.49. The firm’s 50-day simple moving average is $10.09 and its 200-day simple moving average is $11.73. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. The company has a market capitalization of $1.03 billion, a PE ratio of -1.94 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter in the previous year, the company earned $0.41 EPS. Integra LifeSciences’s revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts predict that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Integra LifeSciences News Roundup

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 beat on both EPS and revenue: Integra reported $0.54 EPS (vs. ~$0.41 consensus) and revenue of $391.9M (above estimates), showing sequential improvement and operating leverage that beat Street expectations. Zacks: Beats Q1 Estimates
• Positive Sentiment: FY2026 EPS guidance raised/above consensus: Management set FY2026 EPS at $2.40–$2.50, which is modestly above consensus, suggesting confidence in full-year profitability trajectory. This helps justify a re-rating despite mixed near-term guidance. GlobeNewswire: Q1 Financial Results
• Positive Sentiment: Planned leadership transition with internal promotion: Integra named Stuart Essig as next CEO and moved Michael McBreen to Chief Commercial Officer — a succession plan that signals continuity and may reassure investors about execution of commercial strategy. GlobeNewswire: Leadership Transition
• Neutral Sentiment: Company released supplemental materials and a conference call/slide deck for additional detail—useful for investors who want to drill into segment trends and margin drivers. MarketBeat: Call & Materials
• Negative Sentiment: Q2 guidance came in light of Street expectations: management set Q2 EPS at $0.44–$0.52 (below the ~$0.53 consensus) and revenue guidance of $410M–$425M (slightly below consensus midpoint), leaving some near-term execution risk. GlobeNewswire: Q1 Results & Guidance
• Negative Sentiment: Company still reports a negative net margin at the moment (reflecting legacy costs and restructuring/interest impacts), which is a reminder that profitability improvements remain a multi-quarter process. MarketBeat: Financial Snapshot

Institutional Trading of Integra LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Integra LifeSciences during the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. grew its position in shares of Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after buying an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Integra LifeSciences by 23.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after buying an additional 45,693 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Integra LifeSciences during the 2nd quarter worth approximately $491,000. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.